Gilead Sciences Strengthens Commitment to Inflammatory Disease with New Research Centre
Wednesday 14th February 2024, Oxford, UK – Gilead Sciences Ltd. On 14 February, Gilead Sciences held a ribbon-cutting event to celebrate the opening of its new research site at the Business Park in Oxford. With capacity for up to 60 research scientists and employees, the site will play a role in helping to drive innovation in the UK life sciences sector, with the ambition of bringing forward new medicines for patients living with inflammatory diseases.
Flavius Martin, Executive Vice President, Research, Gilead Sciences, says: “Our new Oxford site will enable us to continue our pivotal research in autoimmune conditions such as inflammatory bowel disease, rheumatoid arthritis, and lupus. The opening of the site extends our impact globally – being Gilead’s first research hub outside the United States – and places Oxford at the forefront of addressing healthcare needs of people living with these debilitating diseases.”
Lynne Murray, Vice President, Head of UK Research, Site Head for Oxford, Gilead Sciences, says: “It has been fantastic to integrate the incredible minds at MiroBio into the Gilead family and we are delighted to take the next step with the opening of this new research centre in Oxford. We are excited about the potential to advance scientific knowledge and bring forward new transformative therapies for inflammatory diseases.”
Anneliese Dodds, MP for Oxford East, comments: “I am delighted that Gilead has chosen Oxford for its new research site, its first outside the USA. It builds on our city’s strength in biotech research, and is a testament to the growing and vibrant innovation ecosystem surrounding Oxford University.”
Gilead, a global pharmaceutical company, acquired MiroBio, an Oxford-backed research company, in 2022. Gilead is headquartered in Foster City, California, with additional UK sites in central London, Cambridge and Stockley Park, Uxbridge. MiroBio was originally spun out of Oxford University in 2019 and was based on more than 15 years of foundational research from Oxford University laboratories.
